# Safety and Dose Study of GRN163L to Treat Patients With Chronic Lymphoproliferative Disease(CLD)

> **NCT00124189** · PHASE1 · COMPLETED · sponsor: **Geron Corporation** · enrollment: 48 (estimated)

## Conditions studied

- Chronic Lymphoproliferative Diseases

## Interventions

- **DRUG:** GRN163L

## Key facts

- **NCT ID:** NCT00124189
- **Lead sponsor:** Geron Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** 2013-03
- **Final completion:** 2013-03
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2015-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00124189

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00124189, "Safety and Dose Study of GRN163L to Treat Patients With Chronic Lymphoproliferative Disease(CLD)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00124189. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*